Picture of Stoke Therapeutics logo

STOK — Stoke Therapeutics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapNeutral

Stoke Therapeutics Inc expected to post earnings of 36  cents a share - Earnings Preview

* Stoke Therapeutics Inc  STOK.OQ   STOK.O  is expected
to show a
rise in quarterly revenue when it reports  results on May 9
(estimated). 
    * The Bedford Massachusetts-based  company is expected to
report
revenue of $40 million, according to the mean estimate from 9
analysts, based on Refinitiv data.  
    * ​Refinitiv's mean analyst estimate for Stoke Therapeutics
Inc is
for earnings of 36 cents per share. For the same quarter last
year, the company reported a loss of 46 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 11 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Stoke
Therapeutics Inc is $65​, above​ its last closing price
of $14.06. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2021  -0.64       -0.62      -0.66     Missed  -5.9
 Sep. 30 2021  -0.61       -0.59      -0.61     Missed  -3.8
 Jun. 30 2021  -0.45       -0.47      -0.60     Missed  -27.7​
 Mar. 31 2021  -0.44       -0.44      -0.46     Missed  -4.5
 ​​Dec.        -0.41       -0.42      -0.42     Met     -0.2
 31 2020                                                
 Sep. 30 2020  -0.44       -0.41      -0.41     Met     1​
 Jun. 30 2020  -0.36       -0.35      -0.39     Missed  -10
 Mar. 31 2020  -0.36       -0.36      -0.34     Beat    4.5
 This summary was machine generated May 6 at 18:30 GMT.  All
figures in US dollars  unless otherwise stated

Recent news on Stoke Therapeutics

See all news